TRUTAKNA® (atacicept) has been FDA approved for IgAN, click to learn more. FILSPARI® (sparsentan) has also been FDA approved for FSGS and more information is coming soon. Please visit our Patient Navigation tool for support.
At NephCure, our mission is fueled by the passion and commitment of our diverse team, united in the fight against rare, protein-spilling kidney diseases. Get to know the faces behind the mission.
Explore career opportunities at NephCure, where passion meets purpose. Our dedicated team is committed to advancing research, supporting patients, and raising awareness for rare kidney diseases. Explore rewarding career opportunities today.
JOIN THE TEAM